Bridger Management’s Nautilus Biotechnolgy NAUT Stock Holding History

Bridger Management’s Portfolio NAUT Stock Details NAUT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-413,700	Closed	-$877K	–	34
2022 Q3	$877K	Buy	413,700 +124,700	+43%	+$314K	0.27%	39
2022 Q2	$777K	Hold	289,000	–	–	0.18%	38
2022 Q1	$1.25M	Hold	289,000	–	–	0.21%	46
2021 Q4	$1.5M	Buy	289,000 +163,000	+129%	+$872K	0.19%	39
2021 Q3	$774K	Buy	126,000 +69,000	+121%	+$550K	0.09%	43
2021 Q2	$576K	Buy	+57,000	New	+$617K	0.05%	43

Other funds holding NAUT

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Cercano Management Bellevue, Washington $750M AUM 25.77% 1-Year Est. Return

MVG

Madrona Venture Group Seattle, Washington $22.1M AUM 86.9% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

CFM

Comprehensive Financial Management Los Gatos, California $3.05B AUM 1.77% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return

Tikvah Management Charlotte, North Carolina $329M AUM 64.12% 1-Year Est. Return

ACI

Amazon.com Inc Seattle, Washington $4.42B AUM 22.6% 1-Year Est. Return

ArchPoint Investors Coral Gables, Florida $473M AUM 49.24% 1-Year Est. Return

Bridger Management's NAUT Position: Q4 2022 in Review

Bridger Management sold out of Nautilus Biotechnolgy (NAUT) in Q4 2022, closing a stake of 413,700 shares — an estimated $877K sold.

Bridger Management first reported a position in NAUT in Q2 2021 and held it in 6 quarters. The position peaked at $1.5M in Q4 2021. 81 funds tracked by Wall St. Rank hold NAUT as of Q4 2022.

Bridger Management reported no remaining Nautilus Biotechnolgy position as of Q4 2022 after selling out during the quarter.
Bridger Management sold 413,700 Nautilus Biotechnolgy shares in Q4 2022, an estimated $877K.
Bridger Management first reported a position in Nautilus Biotechnolgy in Q2 2021 and held it in 6 quarters.
Bridger Management's Nautilus Biotechnolgy position peaked at $1.5M in Q4 2021.
81 funds tracked by Wall St. Rank held Nautilus Biotechnolgy as of Q4 2022.

Based on Bridger Management's 13F filing for Q4 2022, filed 15 Feb 2023.